The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: A mechanistic difference between normal and cancer stem cells

Blood Cells, Molecules, and Diseases

Volumn 41, Issue 1, 2008, Pages 73-76

  Yilmaz, Ömer H ^a   Morrison, Sean J ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER STEM CELL; CARCINOGENESIS; COLON CANCER; GENE DELETION; HUMAN; LEUKEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL AGING; FORKHEAD TRANSCRIPTION FACTORS; HEMATOPOIETIC STEM CELLS; LEUKEMIA; MICE; NEOPLASTIC STEM CELLS; PTEN PHOSPHOHYDROLASE; SIROLIMUS;

EID: 44649190505     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.02.004     Document Type: Article

References (55)

1. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., and Dick J.E. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 17 (1994) 645-648
2. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med, 3 (1997) 730-737
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3983-3988
4. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., and Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15178-15183
5. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., and Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63 (2003) 5821-5828
6. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., and Dirks P.B. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
7. O'Brien C.A., Pollett A., Gallinger S., and Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
8. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., and De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (2007) 111-115
9. Spangrude G.J., Heimfeld S., and Weissman I.L. Purification and characterization of mouse hematopoietic stem cells. Science 241 (1988) 58-62
10. Morrison S.J., and Weissman I.L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1 (1994) 661-673
11. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., and Strasser A. Tumor growth need not be driven by rare 'cancer stem cells'. Science 317 (2007) 337
12. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., and Morrison S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482
13. Lessard J., and Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature 423 (2003) 255-260
14. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., Morrison S.J., and Clarke M.F. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 (2003) 302-305
15. van der Lugt N.M.T., Alkema M.J., Berns A., and Deschamps J. The Polycomb-group homolog Bmi-1 is a regulator of murine Hox gene expression. Mech. Dev. 58 (1996) 153-164
16. Molofsky A.V., He S., Kruger G.M., Bydon M., Morrison S.J., and Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 19 (2005) 1432-1437
17. Molofsky A.V., Pardal R., Iwashita T., Park I.K., Clarke M.F., and Morrison S.J. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425 (2003) 962-967
18. Park I.-K., Qian D., Kiel M., Becker M., Pihalja M., Weissman I.L., Morrison S.J., and Clarke M. Bmi-1 is required for the maintenance of adult self-renewing hematopoietic stem cells. Nature 423 (2003) 302-305
19. Hock H., Hamblen M.J., Rooke H.M., Schindler J.W., Saleque S., Fujiwara Y., and Orkin S.H. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature 431 (2004) 1002-1007
20. Hock H., Meade E., Medeiros S., Schindler J.W., Valk P.J., Fujiwara Y., and Orkin S.H. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev. 18 (2004) 2336-2341
21. Kato Y., Iwama A., Tadokoro Y., Shimoda K., Minoguchi M., Akira S., Tanaka M., Miyajima A., Kitamura T., and Nakauchi H. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J. Exp. Med. 202 (2005) 169-179
22. Passegue E., Wagner E.F., and Weissman I.L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119 (2004) 431-443
23. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
24. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev., Cancer 6 (2006) 184-192
25. Levine A.J., Feng Z., Mak T.W., You H., and Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 20 (2006) 267-275
26. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., Wu H., and Li L. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441 (2006) 518-522
27. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37 (2005) 19-24
28. Liu T.C., Lin P.M., Chang J.G., Lee J.P., Chen T.P., and Lin S.F. Mutation analysis of PTEN/MMAC1in acute myeloid leukemia. Am. J. Hematol. 63 (2000) 170-175
29. Aggerholm A., Gronbaek K., Guldberg P., and Hokland P. Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur. J. Haematol. 65 (2000) 109-113
30. Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., and Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 92 (1998) 3410-3415
31. Simpson P. Notch and the choice of cell fate in Drosophila neuroepithelium. Trends Genet. 6 (1990) 343-345
32. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 22 (2003) 183-198
33. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., Kornblum H.I., Liu X., and Wu H. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294 (2001) 2186-2189
34. Wang S., Garcia A.J., Wu M., Lawson D.A., Witte O.N., and Wu H. Pten deletion leads to the expansion of a prostate stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1480-1485
35. Knobbe C.B., Merlo A., and Reifenberger G. Pten signaling in gliomas. Neuro-Oncology 4 (2002) 196-211
36. Sulis M.L., and Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 13 (2003) 478-483
37. Recher C., Beyne-Rauzy O., Demur C., Chicanne G., Dos Santos C., Mas V.M., Benzaquen D., Laurent G., Huguet F., and Payrastre B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105 (2005) 2527-2534
38. Recher C., Dos Santos C., Demur C., and Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4 (2005) 1540-1549
39. Abraham R.T., and Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 13 (2007) 3109-3114
40. Margolin K., Longmate J., Baratta T., Synold T., Christensen S., Weber J., Gajewski T., Quirt I., and Doroshow J.H. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104 (2005) 1045-1048
41. Chang S.M., Wen P., Cloughesy T., Greenberg H., Schiff D., Conrad C., Fink K., Robins H.I., De Angelis A., Raizer J., Hess K., Aldape K., Lamborn K.R., Kuhn J., Dancey J., and Prados M.D. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
42. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., and Lowe S.W. Survival signalling by Akt and elF4E in oncogenesis and cancer therapy. Nature 428q (2004) 332-337
43. Ghosh S., Tergaonkar V., Rothlin C.V., Correa R.G., Bottero V., Bist P., Verma I.M., and Hunter T. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 10 (2006) 215-226
44. Chen B.P., Fraser C., Reading C., Murray L., Uchida N., Galy A., Sasaki D., Tricot G., Jagannath S., Barlogie B., et al. Cytokine-mobilized peripheral blood CD34 + Thy-1 +Lin-human hematopoietic stem cells as target cells for transplantation-based gene therapy. Leukemia 9 Suppl 1 (1995) S17-S25
45. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
46. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
47. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
48. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
49. Zeng Z., Sarbassov dos D., Samudio I.J., Yee K.W., Munsell M.F., Ellen Jackson C., Giles F.J., Sabatini D.M., Andreeff M., and Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109 (2007) 3509-3512
50. Greer E.L., and Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24 (2005) 7410-7425
51. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., McDowell E.P., Lazo-Kallanian S., Williams I.R., Sears C., Armstrong S.A., Passegue E., DePinho R., and Gilliland D.G. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128 (2007) 325-339
52. Miyamoto K., Araki K.Y., Naka K., Arai F., Takubo K., Yamazaki S., Matsuoka S., Miyamoto T., Ito K., Ohmura M., Chen C., Hosokawa K., Nakauchi H., Nakayama K., Nakayama K.I., Harada M., Motoyama N., Suda T., and Hirao A. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1 (2007) 101-112
53. Paik J.H., Kollipara R., Chu G., Ji H., Xiao Y., Ding Z., Miao L., Tothova Z., Horner J.W., Carrasco D.R., Jiang S., Gilliland D.G., Chin L., Wong W.H., Castrillon D.H., and DePinho R. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128 (2007) 309-323
54. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
55. Rossi D.J., and Weissman I.L. Pten, tumorigenesis, and stem cell self-renewal. Cell 125 (2006) 229-231